Filtreler
Evaluation of the protective effect of agmatine against cisplatin nephrotoxicity with 99mTc-DMSA renal scintigraphy and cystatin-C

Salihoglu Y.S. | Elri T. | Gulle K. | Can M. | Aras M. | Ozacmak H.S. | Cabuk M.

Article | 2016 | Renal Failure38 ( 9 ) , pp.1496 - 1502

Background: The aim of the current study was to investigate whether agmatine (AGM) has a protective effect against cisplatin-induced nephrotoxicity. Materials and methods: Thirty-two rats were randomly divided into four groups: (1) Saline (control); (2) Cisplatin (CDDP; 7.5 mg/kg intraperitoneally); (3) Agmatine (AGM; 10 mg/kg intraperitoneally); (4) Cisplatin plus agmatine (CDDP + AGM). Agmatine was given before and two consecutive days after cisplatin injection. All the animals underwent renal scintigraphy with 99mTc-DMSA. The levels of serum creatinine, cystatin C, and blood urea nitrogen (BUN) were measured in addition to examin . . .ation of the tissue samples with light microscopy. Acute renal injury was assessed with biochemical analyses, scintigraphic imaging, and histopathological evaluation. Results: In the cisplatin group, the levels of BUN, creatinine, and cystatin C were significantly higher than that of the controls. Histopathological examination showed remarkable damage of tubular and glomerular structures. Additionally, cisplatin caused markedly decreased renal 99mTc-DMSA uptake. AGM administration improved renal functions. Serum creatinine, BUN, and cystatin C levels had a tendency to normalize and, scintigraphic and histopathological findings showed significantly less evidence of renal toxicity than those observed in animals receiving cisplatin alone. Conclusions: Our data indicate that AGM has a protective effect against cisplatin-induced nephrotoxicity. Therefore, it may improve the therapeutic index of cisplatin. In addition, the early renal damage induced by cisplatin and protective effects of AGM against cisplatin nephrotoxicity was accurately demonstrated with 99mTc-DMSA renal scintigraphy. © 2016 Informa UK Limited, trading as Taylor & Francis Group Daha fazlası Daha az

The evaluation of cystatin C, IL-1 beta, and TNF-alpha levels in total saliva and gingival crevicular fluid from 11- to 16-year-old children

Ulker, A. Evren | Tulunoglu, Oezlem | Ozmeric, Nurdan | Can, Murat | Demirtas, Selda

Article | 2008 | JOURNAL OF PERIODONTOLOGY79 ( 5 ) , pp.854 - 860

Background: The aim of this study was to evaluate the levels of cystatin C, interleukin-1 beta (IL-1 beta), and tumor necrosis factor-alpha (TNF-alpha) in the total saliva and gingival crevicular fluid (GCF) of periodontally healthy children (PHC) and children with gingivitis (CG) who were between I I and 16 years old. Methods: The study was carried out with 10 PHC and 25 CG. Unstimulated total saliva and GCF samples were obtained. Clinical parameters, including probing depth (PD), clinical attachment loss (CAL), plaque index (PI), gingival index (GI), and gingival bleeding index (GBI), were assessed. GCF samples were collected from . . . four maxillary upper incisors. After sampling, biochemical analyses were performed using latex particle-enhanced turbidimetric immunoassay for cystatin C and enzyme-linked immunosorbent assay for IL-1 beta and TNF-alpha. The multivariate analysis of variance test was used for statistical evaluation. Results: In total saliva, cystatin C and TNF-a levels were higher in PHC, and IL-1 beta levels were higher in CG, but the differences were not statistically significant. In GCF, cystatin C levels were higher in PHC (P >0.05), whereas TNF-alpha and IL-1 beta levels were higher in CG (P >0.05). In the CG group, there were positive correlations between the GCF cystatin C level and the PI of the sampled site (r = 0.488; P Daha fazlası Daha az

Is cystatin C a reliable renal marker in trauma?

Can, M | Demirtas, S | Polat, O | Yildiz, A

Letter | 2006 | CLINICAL CHEMISTRY AND LABORATORY MEDICINE44 ( 4 ) , pp.510 - 511

WOS: 000236956300028 PubMed: 16599852

6698 sayılı Kişisel Verilerin Korunması Kanunu kapsamında yükümlülüklerimiz ve çerez politikamız hakkında bilgi sahibi olmak için alttaki bağlantıyı kullanabilirsiniz.

creativecommons
Bu site altında yer alan tüm kaynaklar Creative Commons Alıntı-GayriTicari-Türetilemez 4.0 Uluslararası Lisansı ile lisanslanmıştır.
Platforms